TargetMol
Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
More Information
Supplier Page
TargetMol
TargetMol
TargetMol
Lappaconitine hydrobromide (Allapinine) is a kind of alkaloid extracted from Aconitum sinomontanum Nakai. It has anti-inflammatory effects.
More Information
Supplier Page
TargetMol
Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
More Information
Supplier Page
RBC8
100 mg
| 99.81%
TargetMol
RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.
More Information
Supplier Page
TargetMol
SB705498 is a TRPV1 antagonist for hTRPV1. SB-705498 has been investigated for the treatment of Rhinitis, Chronic Cough, and Non-allergic Rhinitis.
More Information
Supplier Page
TargetMol
SB705498 is a TRPV1 antagonist for hTRPV1. SB-705498 has been investigated for the treatment of Rhinitis, Chronic Cough, and Non-allergic Rhinitis.
More Information
Supplier Page
TargetMol
SB705498 is a TRPV1 antagonist for hTRPV1. SB-705498 has been investigated for the treatment of Rhinitis, Chronic Cough, and Non-allergic Rhinitis.
More Information
Supplier Page
TargetMol
Retapamulin, a Pleuromutilin Antibacterial, binds to both E. coli and S. aureus ribosomes with similar potencies (Kd: 3 nM).
More Information
Supplier Page